HRMY Q3'26 Earnings: EPS estimate is 1.09 USD

What happened

Harmony Biosciences Holdings (HRMY) is scheduled to report its third-quarter 2026 results on November 4 before the market opens, with the release expected at 7:30 a.m. ET. The article lists analyst estimates of $272.05 million in revenue and $1.09 earnings per share.

Confirmed

Global impact / market context

The estimates set a reference point for judging the company’s reported sales and earnings. Revenue above or below $272.05 million could signal stronger or weaker demand, while earnings per share—profit allocated to each share—compared with $1.09 can shape expectations for company performance and investor decisions.

Analyst inference

The article lists prior-quarter results alongside estimates: reported revenue exceeded estimates in three of four quarters shown, while earnings per share exceeded estimates in two. These mixed comparisons make the upcoming report’s actual figures and any gap from estimates relevant to investor positioning.

Confirmed

What to watch

1. Check the November 4 release for actual revenue against the $272.05 million estimate; the difference will show whether sales were above or below expectations. Analyst inference
2. Compare reported earnings per share with the $1.09 estimate; a gap could change how investors assess recent profitability, though the article gives no forecast for the result. Analyst inference
3. The article schedules disclosure for 7:30 a.m. ET before the market opens on November 4; confirm whether results are released at that stated time. Confirmed

Evidence

• Original source link unavailable